A safer CAR T-cell therapy for recurrent glioblastoma
Part of Cancer clinical trials.
This trial tests a new type of CAR T-cell therapy that targets a specific protein (EGFRvIII) found on some glioblastoma cells. The treatment is designed to be more effective and potentially safer for people whose brain tumor has come back after previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have a confirmed diagnosis of glioblastoma that has come back (recurrent) and has a specific protein called EGFRvIII.
- You must have good enough organ function (like heart, lungs, kidneys, and liver) to handle the therapy.
- You must be willing to use effective birth control for 12 months after treatment.
- You must not have other serious health conditions like active infections or other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special immune cell treatment (CAR-T cells) that targets two proteins found on glioblastoma cells. It is for patients whose tumor has come back or not responded to standard treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) made from donor cells, designed to target tumors with a specific marker called CD70. It is for people whose brain glioma has come back or hasn't responded to standard treatments.
This Phase 1 trial tests a new immune treatment made from your own immune cells to attack glioblastoma (a brain tumor), especially tumors with a specific EGFR change called EGFRvIII. It mainly focuses on safety and early signs of effectiveness, and some participants will also need surgery/biopsy and an implanted port for the treatment.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests a new type of immunotherapy called CAR-T cells, made from donor cells, for people whose glioblastoma (a type of brain cancer) has come back after standard treatment. The goal is to see if it can shrink the tumor or slow its growth.
This trial tests a new CAR-T cell treatment (SNC-109) for people with glioblastoma that has come back after initial treatment. The therapy uses your own immune cells, modified in a lab, to try to attack the tumor.
Hear when a new Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.